tiprankstipranks
Dianthus Therapeutics (DNTH)
NASDAQ:DNTH
US Market
DNTH
Dianthus Therapeutics
RESEARCH TOOLSreports
Want to see DNTH full AI Analyst Report?

Dianthus Therapeutics (DNTH) Stock Forecast & Price Target

440 Followers
See the Price Targets and Ratings of:

DNTH Analyst Ratings

Strong Buy
12Ratings
Strong Buy
12 Buy
0 Hold
0 Sell
Based on 12 analysts giving stock ratings to
Dianthus
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

DNTH Stock 12 Month Forecast

Average Price Target

$130.63
▲(40.07% Upside)
Based on 12 Wall Street analysts offering 12 month price targets for Dianthus Therapeutics in the last 3 months. The average price target is $130.63 with a high forecast of $200.00 and a low forecast of $98.00. The average price target represents a 40.07% change from the last price of $93.26.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"16":"$16","201":"$201","62.25":"$62.3","108.5":"$108.5","154.75":"$154.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":200,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$200.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":130.625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$130.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":98,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$98.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[16,62.25,108.5,154.75,201],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Sep<br/>2025","6":"Dec<br/>2025","9":"Mar<br/>2026","12":"Jun<br/>2026","25":"Jun<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.45,97.95384615384616,106.45769230769231,114.96153846153845,123.46538461538461,131.96923076923076,140.47307692307692,148.97692307692307,157.48076923076923,165.98461538461538,174.48846153846154,182.9923076923077,191.49615384615385,{"y":200,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.45,92.61730769230769,95.78461538461539,98.95192307692308,102.11923076923077,105.28653846153847,108.45384615384616,111.62115384615385,114.78846153846155,117.95576923076923,121.12307692307692,124.29038461538462,127.45769230769231,{"y":130.625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,89.45,90.1076923076923,90.76538461538462,91.42307692307692,92.08076923076923,92.73846153846154,93.39615384615385,94.05384615384615,94.71153846153847,95.36923076923077,96.02692307692308,96.68461538461538,97.34230769230768,{"y":98,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":17.53,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.59,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":23.85,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 37,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":38.93,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 31,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":34.98,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":43.2,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.21,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":53.18,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":55.26,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":84.56,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":87.42,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 33,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":89.45,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$200.00Average Price Target$130.63Lowest Price Target$98.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DNTH
Sadia Rahman
Wells Fargo
Wells Fargo
$135
Buy
44.76%
Upside
Assigned
06/17/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Wedbush Analyst forecast on DNTH
Laura Chico
Wedbush
Wedbush
$105
Buy
12.59%
Upside
Reiterated
06/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Dianthus Therapeutics (NASDAQ: DNTH) and Aurora Cannabis (NASDAQ: ACB)
Truist Financial Analyst forecast on DNTH
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Dianthus Therapeutics (NASDAQ: DNTH)
Jefferies Analyst forecast on DNTH
Maury Raycroft
Jefferies
Jefferies
$132
Buy
41.54%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Medpace Holdings (NASDAQ: MEDP)
TD Cowen Analyst forecast on DNTH
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/12/26
TD Cowen Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)
LifeSci Capital Analyst forecast on DNTH
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$65→$125
Buy
34.03%
Upside
Assigned
06/12/26
Analyst Maintains Buy Rating on Claseprubart Developer, Keeps $125 Price Target Unchanged Amid Confidence in Trial Design and Potency
Raymond James Analyst forecast on DNTH
Ryan Deschner
Raymond James
Raymond James
―
Buy
―
Reiterated
06/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DNTH
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$130
Buy
39.40%
Upside
Reiterated
06/11/26
Analyst Reiterates Buy on Dianthus Therapeutics, Keeping $130 Price Target Amid Confidence in Claseprubart’s Best-in-Class Potential
William Blair Analyst forecast on DNTH
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
06/10/26
Analysts' Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM)
Evercore ISI Analyst forecast on DNTH
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$122→$120
Buy
28.67%
Upside
Reiterated
05/11/26
Dianthus price target lowered to $120 from $122 at Evercore ISIDianthus price target lowered to $120 from $122 at Evercore ISI
Guggenheim Analyst forecast on DNTH
Yatin Suneja
Guggenheim
Guggenheim
$200
Buy
114.45%
Upside
Reiterated
05/06/26
Dianthus Therapeutics (DNTH) Receives a Buy from Guggenheim
Wolfe Research Analyst forecast on DNTH
Andy Chen
Wolfe Research
Wolfe Research
$98
Buy
5.08%
Upside
Reiterated
04/08/26
Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
Stifel Nicolaus Analyst forecast on DNTH
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$65→$120
Buy
28.67%
Upside
Reiterated
03/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanobiotix (NASDAQ: NBTX), ImageneBio (NASDAQ: IMA) and Dianthus Therapeutics (NASDAQ: DNTH)
Clear Street Analyst forecast on DNTH
William Maughan
Clear Street
Clear Street
$100→$130
Buy
39.40%
Upside
Reiterated
03/10/26
Dianthus price target raised to $130 from $100 at Clear StreetDianthus price target raised to $130 from $100 at Clear Street
Robert W. Baird Analyst forecast on DNTH
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$67→$132
Buy
41.54%
Upside
Reiterated
03/09/26
Dianthus price target raised to $132 from $67 at BairdDianthus price target raised to $132 from $67 at Baird
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Wells Fargo Analyst forecast on DNTH
Sadia Rahman
Wells Fargo
Wells Fargo
$135
Buy
44.76%
Upside
Assigned
06/17/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Rhythm Pharmaceuticals (NASDAQ: RYTM)
Wedbush Analyst forecast on DNTH
Laura Chico
Wedbush
Wedbush
$105
Buy
12.59%
Upside
Reiterated
06/15/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Genmab (NASDAQ: GMAB), Dianthus Therapeutics (NASDAQ: DNTH) and Aurora Cannabis (NASDAQ: ACB)
Truist Financial Analyst forecast on DNTH
Danielle Brill
Truist Financial
Truist Financial
―
Buy
―
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Jazz Pharmaceuticals (NASDAQ: JAZZ) and Dianthus Therapeutics (NASDAQ: DNTH)
Jefferies Analyst forecast on DNTH
Maury Raycroft
Jefferies
Jefferies
$132
Buy
41.54%
Upside
Reiterated
06/15/26
Analysts Offer Insights on Healthcare Companies: Dianthus Therapeutics (NASDAQ: DNTH) and Medpace Holdings (NASDAQ: MEDP)
TD Cowen Analyst forecast on DNTH
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
06/12/26
TD Cowen Keeps Their Buy Rating on Dianthus Therapeutics (DNTH)
LifeSci Capital Analyst forecast on DNTH
Rami Katkhuda
LifeSci Capital
LifeSci Capital
$65→$125
Buy
34.03%
Upside
Assigned
06/12/26
Analyst Maintains Buy Rating on Claseprubart Developer, Keeps $125 Price Target Unchanged Amid Confidence in Trial Design and Potency
Raymond James Analyst forecast on DNTH
Ryan Deschner
Raymond James
Raymond James
―
Buy
―
Reiterated
06/12/26
Wall Street Analysts Are Bullish on Top Healthcare Picks
H.C. Wainwright Analyst forecast on DNTH
Swayampakula Ramakanth
H.C. Wainwright
H.C. Wainwright
$130
Buy
39.40%
Upside
Reiterated
06/11/26
Analyst Reiterates Buy on Dianthus Therapeutics, Keeping $130 Price Target Amid Confidence in Claseprubart’s Best-in-Class Potential
William Blair Analyst forecast on DNTH
Myles Minter
William Blair
William Blair
―
Buy
―
Reiterated
06/10/26
Analysts' Top Healthcare Picks: Dianthus Therapeutics (DNTH), Cullinan Management (CGEM)
Evercore ISI Analyst forecast on DNTH
Gavin Clark-Gartner
Evercore ISI
Evercore ISI
$122→$120
Buy
28.67%
Upside
Reiterated
05/11/26
Dianthus price target lowered to $120 from $122 at Evercore ISIDianthus price target lowered to $120 from $122 at Evercore ISI
Guggenheim Analyst forecast on DNTH
Yatin Suneja
Guggenheim
Guggenheim
$200
Buy
114.45%
Upside
Reiterated
05/06/26
Dianthus Therapeutics (DNTH) Receives a Buy from Guggenheim
Wolfe Research Analyst forecast on DNTH
Andy Chen
Wolfe Research
Wolfe Research
$98
Buy
5.08%
Upside
Reiterated
04/08/26
Bullish View on Dianthus: Claseprubart’s Differentiated Complement Inhibition and Underappreciated Bifunctional Pipeline Drive Buy Rating
Stifel Nicolaus Analyst forecast on DNTH
Alex Thompson CFA
Stifel Nicolaus
Stifel Nicolaus
$65→$120
Buy
28.67%
Upside
Reiterated
03/10/26
Analysts Have Conflicting Sentiments on These Healthcare Companies: Nanobiotix (NASDAQ: NBTX), ImageneBio (NASDAQ: IMA) and Dianthus Therapeutics (NASDAQ: DNTH)
Clear Street Analyst forecast on DNTH
William Maughan
Clear Street
Clear Street
$100→$130
Buy
39.40%
Upside
Reiterated
03/10/26
Dianthus price target raised to $130 from $100 at Clear StreetDianthus price target raised to $130 from $100 at Clear Street
Robert W. Baird Analyst forecast on DNTH
Colleen M. Kusy
Robert W. Baird
Robert W. Baird
$67→$132
Buy
41.54%
Upside
Reiterated
03/09/26
Dianthus price target raised to $132 from $67 at BairdDianthus price target raised to $132 from $67 at Baird
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Dianthus Therapeutics

3 Months
Gavin Clark-GartnerEvercore ISI
Success Rate
7/7 ratings generated profit
100%
Average Return
+55.06%
Copying Gavin Clark-Gartner's trades and holding each position for 3 Months would result in 100.00% of your transactions generating a profit, with an average return of +55.06% per trade.
1 Year
Gavin Clark-GartnerEvercore ISI
Success Rate
7/7 ratings generated profit
100%
Average Return
+182.60%
Copying Gavin Clark-Gartner's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +182.60% per trade.
2 Years
Alex Thompson CFAStifel Nicolaus
Success Rate
10/10 ratings generated profit
100%
Average Return
+213.22%
Copying Alex Thompson CFA's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +213.22% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

DNTH Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
4
14
13
13
8
Buy
9
18
16
20
17
Hold
0
0
0
1
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
13
32
29
34
26
In the current month, DNTH has received 25 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. DNTH average Analyst price target in the past 3 months is 130.63.
Each month's total comprises the sum of three months' worth of ratings.

DNTH Financial Forecast

DNTH Earnings Forecast

Next quarter’s earnings estimate for DNTH is -$0.85 with a range of -$1.23 to -$0.52. The previous quarter’s EPS was -$0.85. DNTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DNTH has Performed in-line its overall industry.
Next quarter’s earnings estimate for DNTH is -$0.85 with a range of -$1.23 to -$0.52. The previous quarter’s EPS was -$0.85. DNTH beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year DNTH has Performed in-line its overall industry.

DNTH Sales Forecast

Next quarter’s sales forecast for DNTH is $297.00K with a range of $0.00 to $1.00M. The previous quarter’s sales results were $463.00K. DNTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DNTH has Performed in-line its overall industry.
Next quarter’s sales forecast for DNTH is $297.00K with a range of $0.00 to $1.00M. The previous quarter’s sales results were $463.00K. DNTH beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year DNTH has Performed in-line its overall industry.

DNTH Stock Forecast FAQ

What is DNTH’s average 12-month price target, according to analysts?
Based on analyst ratings, Dianthus Therapeutics’s 12-month average price target is 130.63.
    What is DNTH’s upside potential, based on the analysts’ average price target?
    Dianthus Therapeutics has 40.07% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is DNTH a Buy, Sell or Hold?
          Dianthus Therapeutics has a consensus rating of Strong Buy which is based on 12 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Dianthus Therapeutics’s price target?
            The average price target for Dianthus Therapeutics is 130.63. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $200.00 ,the lowest forecast is $98.00. The average price target represents 40.07% Increase from the current price of $93.26.
              What do analysts say about Dianthus Therapeutics?
              Dianthus Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 12 Wall Streets Analysts.
                How can I buy shares of DNTH?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.